Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis

Therapeutic effect of nanoliposomal PCSK9 vaccine in a mouse model of atherosclerosis

Abstract Background Proprotein convertase subtilisin/kexin 9 (PCSK9) is an important regulator of low-density lipoprotein receptor (LDLR) and plasma levels of LDL cholesterol (LDL-C). PCSK9 inhibition is an efficient therapeutic approach for the treatment of dyslipidemia. We tested the therapeutic e...

Full description

Bibliographic Details
Main Authors: Amir Abbas Momtazi-Borojeni, Mahmoud Reza Jaafari, Ali Badiee, Maciej Banach, Amirhossein Sahebkar
Format: Article
Language:English
Published: BMC 2019-12-01
Series:BMC Medicine
Subjects:
Atherosclerosis
Low-density lipoprotein cholesterol
PCSK9
Immunotherapy
Online Access:https://doi.org/10.1186/s12916-019-1457-8

Internet

https://doi.org/10.1186/s12916-019-1457-8

Similar Items